Results 191 to 200 of about 180,190 (229)
PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer
Molecular Oncology, EarlyView.Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi +13 morewiley +1 more sourceLDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro
Molecular Oncology, EarlyView.Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber +13 morewiley +1 more sourceFaricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion
Ophthalmology RetinaCarl J. Danzig, Christiana Dinah, Faruque Ghanchi, Lars-Olof Hattenbach, Arshad M. Khanani, Timothy Y.Y. Lai, Masahiko Shimura, Francis Abreu, Pablo Arrisi, Ying Liu, Liliana P. Paris, Anne-Cecile Retiere, Jeffrey R. Willis, Patricio G. Schlottmann, Ashkan Abbey, Elmira Abdulaeva, Santiago Abengoechea, Prema Abraham, Sean Adrean, Hansjürgen Agostini, Arturo Alezzandrini, Daniel Alfaro, Socorro Alforja, Daniel Aliseda, Goncalo Almeida, Payam Amini, Liangbao An, Etelka Aradi, Luis Arias, Sergei Astakhov, Carl Awh, Bulat Aznabaev, Joaquin Bafalluy, Chandra Balaratnasingam, Francesco Bandello, Sanjiv Banerjee, Mark Barakat, Andres Bastien, Ivan Batlle, Rubens Belfort, Brian Berger, Emilia Borcz, Arnaldo Bordon, Michael Briggs, Harold Brooks, David Brown, Jamin Brown, Jacek Brymerski, Maria Budzinskaya, Stuart Burgess, Iksoo Byon, Peter Campochiaro, Andrew Chang, Emmanuel Chang, Caroline Chee, Changzheng Chen, Judy Chen, Shih-Jen Chen, Nicholas Chinskey, Oldrich Chrapek, Salomon Yves Cohen, Juner Colina-Biscotto, Brian Connolly, Pierre Loic Cornut, Hajir Dadgostar, Hong Dai, Carl Danzig, Anthony de Beus, Mario R. del Cid, Amr Dessouki, Christiana Dinah, Antonio Donate, David Eichenbaum, Jan Ernest, Joan Josep Escobar, Andrej Farkas, Nicolas Feltgen, Gloria Ferguson, Philip Ferrone, Joao Figueira, Marta Figueroa, Pablo Franco, Samantha Fraser-Bell, Nicholas Siu Kay Fung, Roberto Gallego-PInazo, Alfredo Garcia-Layana, Maciej Gawecki, Nicola Gan, Faruque Ghanchi, Ghassan Ghorayeb, Fabrizio Giansanti, Manjot Gill, Michaella Goldstein, Fumi Gomi, Jordan Graff, Shailesh Gupta, Mei Han, Ryuya Hashimoto, Lars-Olof Hattenbach, Ken Hayashi, Lina Kobayter Helayhel, Ewa Herba, Vrinda Hershberger, Patrick Higgins, Takao Hirano, Yoshio Hirano, Shigeru Honda, Allen Hu, Stephen Huddleston, Alan A. Hunter, Yih-Shiou Hwang, Tomohiro Iida, Yuichiro Ishida, Golnaz Javey, Cameron Javid, Jakub Kaluzny, Hiroki Kaneko, Se Woong Kang, Hakan Kaymak, Patrick Kelty, Agnes Kerenyi, Arshad Khanani, Rahul Khurana, Jong Woo Kim, Sang Jin Kim, Genichiro Kishino, Namie Kobayashi, Lina Kobayter Helayhel, Bohdan Kousal, Robert Kwun, Alexey Kulikov, Ajay Kuriyan, James Lai, Yuk Yau Timothy Lai, Wai Ching Lam, Daniel Lavinsky, Seong Lee, Xiaorong Li, Xiaoling Liang, Lucas Lindsell, Nikolas London, Peck-Lin Lip, Mimi Liu, Xiaoling Liu, Alan Luckie, Miguel Lume, James K. Luu, Dennis Marcus, Yoshitsugu Matsui, Hemal Mehta, Katarzyna Michalska-Malecka, Yoshinori Mitamura, Quresh Mohamed, Aditi Mohla, Javier Montero, Jeffrey Moore, Ryusaburo Mori, Haia Morori-Katz, Raj Mukherjee, Yuki Muraoka, Maria Muzyka-Wozniak, Jan Nemcansky, Tetsuya Nishimura, Hideyasu Oh, Piotr Oleksy, Kyu Hyung Park, D. Wilkin Parke, Maria Cristina Parravano, Apurva Patel, Sunil Patel, Marc Peden, Fernando Penha, Qing Peng, Nadezhda Pozdeyeva, Dorota Raczynska, Hessam Razavi, Gayatri Reilly, Marek Rekas, Federico Ricci, Richard Roe, Soraya Rofagha, Bozena Romanowska-Dixon, Irit Rosenblatt, Jose Maria Ruiz Moreno, Stefan Sacu, Min Sagong, Yoshitsugu Saishin, Taiji Sakamoto, Sukhpal Sandhu, Laura Sararols, Mario Saravia, Patricio Schlottmann, Tetsuju Sekiryu, András Seres, Ankur Shah, Veeral Sheth, Masahiko Shimura, Bartosz Sikorski, Rufino Silva, Zongming Song +199 moreopenaire +1 more sourcePlecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin
Molecular Oncology, EarlyView.The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor +10 morewiley +1 more sourceRecurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies
Molecular Oncology, EarlyView.We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa +15 morewiley +1 more sourcePeroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity
Molecular Oncology, EarlyView.Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski +17 morewiley +1 more sourceCrucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples
Molecular Oncology, EarlyView.This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.Hanne Goris, Vasiliki Siozopoulou, Léon C van Kempen, Anne Sieben, Ella Roelant, Stig Hellemans, Elyne Backx, Laure Sorber, Koen De Winne, Senada Koljenović, Karen Zwaenepoel +10 morewiley +1 more source
